Related Experiment Video
Updated: Feb 9, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Emerging problems in the treatment of pediatric community-acquired pneumonia
Nicola Principi1, Susanna Esposito2
1a Università degli Studi di Milano , Milano , Italy.
Insights
Community-acquired pneumonia (CAP) in children remains a significant health issue. Current treatment guidelines, with amoxicillin as the primary choice, are effective, but further research is needed for optimal outcomes.
Area of Science:
- Pediatric infectious diseases
- Respiratory medicine
Background:
- Community-acquired pneumonia (CAP) is a leading cause of childhood illness and mortality globally, particularly in children under five.
- Existing treatment guidelines for pediatric CAP are crucial for managing this common disease in industrialized nations.
Purpose of the Study:
- To discuss emerging challenges and evaluate current treatment strategies for pediatric CAP.
- To assess the evidence supporting the use of macrolides, corticosteroids, and vitamin supplementation in pediatric CAP management.
Main Methods:
- Review of current therapeutic approaches and official recommendations for pediatric CAP.
- Analysis of existing evidence regarding the efficacy of various treatment modalities, including antibiotics, corticosteroids, and supplements.
Main Results:
- Amoxicillin is confirmed as the preferred antibiotic for pediatric CAP.
- Evidence supporting the routine use of macrolides, corticosteroids, or vitamin C/D supplementation is currently insufficient.
- Corticosteroids may benefit cases with bronchoconstriction, but their role in severe inflammation requires further study.
Conclusions:
- Current treatment recommendations for pediatric CAP remain the best approach in industrialized countries.
- Further research is essential to refine treatment protocols and improve the prognosis of pediatric CAP.
- Evidence-based modifications to current guidelines are needed to enhance the management of pediatric CAP.
Introduction:
Community-acquired pneumonia (CAP) remains one of the most common reasons for paediatric morbidity and accounts for about 16% of all the deaths occurring in children less than 5 years of age. Areas covered: The main aim of this paper is to discuss the emerging problems for CAP treatment in paediatric age. Expert commentary: Official recommendations for therapeutic approaches to paediatric CAP, despite being not very recent, seem still to be the best solution to assure the highest probabilities of cure for children with this disease living in industrialized countries. Amoxicillin remains the drug of choice and use of macrolides alone or in combination does not seem supported by solid evidence. Corticosteroids can be useful in CAP associated with bronco-obstruction, whereas their effectiveness in cases with a severe inflammatory response, although plausible, is not supported by data collected through randomized, placebo-controlled trials. Finally, for the administration of vitamin C and vitamin D, the available data are not adequate to draw firm conclusions regarding the real importance of supplementation. Further studies are needed to evaluate which modifications of presently available recommendations for paediatric CAP treatment can improve final prognosis of this still common disease.
Related Concept Videos
What are Populations and Communities?
Emerging Adulthood
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Introduction Cardiac Emergencies
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

